
# The Tumor Microenvironment (TME):



#### Matthew Spitzer, PhD University of California, San Francisco



San Francisco

I have the following financial relationships to disclose:

Shareholder and Director: Teiko.Bio

Consultant for: Five Prime, Ono, January, Earli, Astellas, Indaptus


Grant/Research support from: Genentech/Roche, Pfizer, Valitor, Bristol Myers Squibb

Speaker Honorarium: Fluidigm

- and –


I will not discuss off label use and/or investigational use in my presentation.


## Properties of the TME are associated with prognosis



Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival


Curiel et al., Nat. Med., 2004





Schreiber, Old and Smyth, Science, 2011


Solid tumors are complex tissues with a broad diversity of cell types Representative HNSCC




dsDNA, Keratin, E-Cadherin, CD45, Vimentin, CD31

Maha Rahim, Kyle Jones

Advances in single cell analysis provide new perspectives on this diversity




#### Different tumors have unique TMEs




# Human TME archetypes defined by patterns of the cellular infiltrate

Immune Desert CD4 & Macrophages

**Immune Desert CD8 & Macrophages** 



Immune Stroma CD8 Immune Stroma CD4 & Macrophages Immune Desert Monocytes T cell centric Macrophages Pan-Cancer Census of Immune Archetypes




Pan-Cancer Census Immune Archetypes

- Measuring the composition of immune cells in the tumor can classify into 12 groups
- These groups are independent of the cancer tissue-of-origin
- Associations with prognosis within the same tumor type


#### Combes and Samad et al., Cell, 2022

### Defining T cell subsets in the TME




- Single-cell RNAsequencing of tumorinfiltrating T cells
- Integrative analysis
  across 21 different
  tumor types
- The subsets of T cells are conserved across cancers, but significant variability across tumors

#### Many CD8 T cells in the TME are bystanders



# Tissue resident memory T cells (T<sub>RM</sub>) and newly infiltrating CD8 T cells




- T<sub>RM</sub> express molecules that mediate retention in tumors
  - CD103
  - CD69
- Recent studies suggest
  recirculation into lymph
  nodes after activation
- Cell trafficking dynamics between TME and periphery is under active investigation.


Okla et al., J. Exp. Med., 2021

## Tumors can evolve to evade CD8 T cell responses

- Mutations, silencing, or degradation of MHC class I
- Loss of immunogenic neoantigens
- Mutations in antigen processing machinery
- Mutations in IFNγ signaling pathway




# CD4 T cells in the TME




- Different CD4 T cell subsets have opposing functions in the TME
- Recent studies
  identified
  importance for
  effective
  immunotherapy
- Direct recognition
  (MHC class II+
  tumors) and "helper"
  functions

# CD4 T cells in the TME: Opposing functions and cross-regulation



- Treg depletion
  enables cDC2
  trafficking to the
  lymph node
- Antigen presentation drives a CD4 effector cell response


# Dendritic cells: Functions in the TME and in the tdLN



 Antigen uptake in TME and presentation in lymph nodes


New studies identifying roles for supporting T cell responses in the TME

## Unique functions of dendritic cell subsets in the TME




- cDC1s specialized in antigen crosspresentation
- cDC2s are better at priming CD4 T cell responses
- cDC3s recently described but may be a subset of cDC2s
- pDCs can make type 1 IFN but mixed functions

Kvedaraite and Ginhoux, Sci. Immunol., 2022




Bottcher et al., Cell, 2018; Barry et al., Cancer Cell, 2018 Figure from review: Peterson and Barry, Front. Immunol., 2021

# Macrophages in the TME: The M1/M2 Paradigm



- Classically defined from in vitro polarization studies
- Extrapolation to in vivo immune responses


# Macrophage ontogeny: tissue- or bone marrow-derived?



- Macrophages can be replenished from bone marrowderived monocytes
- Early tissue macrophages are derived from embryonic sources
- The balance of these sources of cells is highly tissue-specific

Ginhoux and Guilliams, Immunity, 2016


# Macrophage ontogeny: tissue- or bone marrow-derived?




Ginhoux and Guilliams, Immunity, 2016


# Revisiting Macrophages in the TME: A diversity of cell states

Human Breast Cancers:





## Neutrophils in the TME



- Inflammatory functions can be pro- or anti-tumor
- Cytokines can promote tumor cell growth
- Other mechanisms can be tumoricidal

Cytotoxic


lymphocyte inhibition

CD8<sup>+</sup> T cell

NK cell


• Suppression of T cell responses

## Fibroblasts in the TME



- Substantial focus on tumorpromoting properties of cancer-associated fibroblasts (CAFs)
- Data suggest that fibroblasts can play anti-tumor roles in some contexts

### Dissecting fibroblast diversity in the TME



PDPN-Not in FAPcurrent ENG<sup>+</sup> datasets C7 NM Fib meso ENG<sup>+</sup> CD74<sup>+</sup>  $C7^+$ HLA-DRA<sup>lo</sup> COL1A1<sup>+</sup> COL3A1<sup>+</sup> TIMP1<sup>+</sup> eCAF FAP+ (c1) HAS1+ LRRC15<sup>+</sup> CXCL1+ COL11A<sup>+</sup> CCL2\* ACTA2+ FAP+ FAP CD74<sup>hi</sup> CD74<sup>hi</sup> IL1 CAF TGFB CAF HLA-DRA+ HLA-DRA (C2) (C0) ■ eCAF 44% CAF1 3% TGFβ CAF 52%


Dominguez et al., Cancer Discov., 2020

Buechler and Pradhan et al., Nature, 2021;

## Soluble factors in the TME

Anti-tumor TME


**Pro-tumor TME** 



- Complex cytokine networks mediate cell-cell communication and migration in the TME
- Shape the polarization, differentiation and effector function of each cell type
   Abousaway et al., Nanotheranostics, 2021

### Extracellular matrix in the TME


#### ECM REMODELLING IN THE PRIMARY TUMOUR



Winkler et al., Nat. Comm., 2020


# The metabolic environment of the TME

- Hypoxia
  - Induces HIF1 $\alpha$
- Nutrient poor
  - e.g., glucose consumption, arginine and tryptophan depletion)
- Immunomodulatory metabolites
  - e.g., kynurenine, adenosine



Buck et al., Cell, 2017

# The spatial organization of the TME is associated with prognosis




Triple-negative breast cancer:

Percent survival Percent survival Percent 50-50-50. inflamed inflamed inflamed excluded excluded excluded p=0.0003 p=0.003 p=0.009 gnored ianored gnored 50 100 150 100 150 50 150 50 100 Time [month] Time [month] Time [month]


#### Hammerl et al., Nat. Comm., 2021

### TGF $\beta$ is a regulator of the "excluded" phenotype



Mariathasan et al., Nature, 2018


# The spatial organization of the TME is associated with prognosis




Cold

Keren et al., Cell, 2018

# Cellular hubs with coordinated activity in the TME









Pelka et al., Cell, 2021

### Tertiary lymphoid structures in the TME




- TLS are lymph node-like structures that form ectopically in inflamed tissues
- Variable in their composition, localization and maturation state
- Poorly modeled in mice


# Tertiary lymphoid structures associate with response to checkpoint inhibitor immunotherapy



Cabrita et al., Nature, 2020 (figures) Helmink et al., Nature, 2020 Petitprez et al., Nature, 2020




# The "Cancer Immunity" cycle connects the TME with the rest of the body




#### Chen and Mellman, Immunity, 2013

# The "Cancer Immunity" cycle connects the TME with the rest of the body



#### Chen and Mellman, Immunity, 2013


### The TME communicates with the rest of the body



- Different mouse models of cancer change the peripheral immune system in distinct ways
- Some have dramatic effects across all tissues, while some predominantly impact the tumor-draining lymph node


Allen, Hiam et al., Nat. Med., 2020

# Tumors can alter immune cell development in the bone marrow




Casbon et al., PNAS, 2015; Meyer et al., 2018, Nat. Comm. Figure from review: Hiam-Galvez et al., Nat. Rev. Cancer, 2021


#### Tumors can alter new immune responses



 Mice with established cancers make poor T cell response to new stimuli, such as pathogens.

#### Tumors can alter new immune responses





# **Cancer Cell**


#### Letter

CellPress

# Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer

Sidse Ehmsen,<sup>1,2,3</sup> Anders Asmussen,<sup>4</sup> Stefan S. Jeppesen,<sup>1,2,3</sup> Anna Christine Nilsson,<sup>2,5</sup> Sabina Østerlev,<sup>1</sup> Hanne Vestergaard,<sup>4</sup> Ulrik S. Justesen,<sup>2,6</sup> Isik S. Johansen,<sup>2,7</sup> Henrik Frederiksen,<sup>2,3,4</sup> and Henrik J. Ditzel<sup>1,2,3,8,9,\*</sup> <sup>1</sup>Department of Oncology, Odense University Hospital, Odense, Denmark

# Pre-metastatic niches create a hospitable environment for tumor cells to disseminate



- Before tumor cells metastasize, targeted tissues begin to change
- Infiltration of myeloid cells that drive inflammation and suppress T cells
- Remodeling of ECM and vasculature

Liu and Cao, Cancer Cell, 2106

## Questions?

